Abstract
The treatment landscape for relapsing-remitting multiple sclerosis (RRMS) is rapidly evolving and it is important for treatment decision-makers and policymakers to have information on the comparative efficacy of RRMS medications. Therefore, we conducted a systematic search to identify clinical trials that have compared the efficacy of FDA-approved disease-modifying therapies (DMTs) versus active comparator medications for the treatment of RRMS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
